|
|
|
02.11.26 - 22:39
|
BioArctic collaborator Novartis terminates agreement (PR Newswire)
|
|
|
STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new......
|
|
|
|
|
30.10.26 - 15:27
|
BioArctic′s Nomination Committee appointed (PR Newswire)
|
|
|
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has been appointed in accordance with the principles adopted by the Annual......
|
|
|
|
|
|
|
|
|
|
|
|
|
22.09.26 - 16:45
|
First patient treated with Leqembi® (lecanemab) in Sweden (PR Newswire)
|
|
|
STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a......
|
|
|
22.09.26 - 16:42
|
First patient treated with Leqembi® (lecanemab) in Sweden (PR Newswire)
|
|
|
STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a......
|
|
|
16.09.26 - 08:21
|
Leqembi® Pen subcutaneous formulation approved in Japan (PR Newswire)
|
|
|
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early......
|
|
|
16.09.26 - 08:18
|
Leqembi® Pen subcutaneous formulation approved in Japan (PR Newswire)
|
|
|
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early......
|
|
|
03.09.26 - 15:57
|
Eiskalte Gewinne: AKTIONÄR-Hot-Stock dreht wieder auf (Der Aktionaer)
|
|
|
Mit einem Plus von knapp sieben Prozent gehört die Aktie der skandinavischen Biotech-Gesellschaft BioArctic am Donnerstag zu den stärksten europäischen Nebenwerten. Weitere positive Neuigkeiten schieben den AKTIONÄR-Hot-Stock an, der sich damit wieder an eine entscheidende Widerstandszone heranpirscht....
|
|
|
03.09.26 - 06:01
|
Leqembi® subcutaneous formulation approved for initiation treatment in China (Cision)
|
|
|
Stockholm, Sweden, September 3, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the National Medical Products Administration (NMPA) of China has approved the Leqembi subcutaneous autoinjector formulation (Leqembi SC-AI) as an initiation treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (collectively referred to as early AD).
The application was accepted by the NMPA in January 2026 and was subsequently granted Priority Review designation. Launch in China is planned during Eisai's Fiscal Year 2026 which...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.08.26 - 08:51
|
BioArctic: Interim Report for the period April - June 2026 (PR Newswire)
|
|
|
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to March 2027) of a total of JPY 143.5 billion......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
